On Tuesday, our Under the Radar Moversnewsletter suggested going long on small cap bioprocessing stock Repligen Corporation (NASDAQ: RGEN):
As for Repligen, this one’s a bit more speculative than usual; we’re betting the long-term shape of the chart takes hold, and benefits us in the short run.
You have to take a big step back to see it, but it’s there – there’s....More>>>
On Friday, our Under the Radar Moversnewsletter suggestedsmall cap precision and specialty motion control stock Allied Motion Technologies (NASDAQ: AMOT) as a possible long position:
Finally, we mulled going ahead and getting into another longer-term position today, but managed to talk ourselves out of it… for the time being anyway. We do intend to get into it soon though, when the....More>>>
On Wednesday, our Under the Radar Moversnewsletter suggested going long on small cap drybulkshipping stock Pangaea Logistics Solutions Ltd (NASDAQ: PANL):
As the chart of PANL below shows, the stock’s been getting squeezed into the tip of a converging wedge for the past few weeks, but this week appears to be breaking above the upper boundary of that formation.
What you can’t....More>>>
The U.S. dollar on Tuesday traded firmly higher against its main rivals, extending gains from the last three months of 2016 after stronger-than-expected manufacturing data added to the bucks uptrend.
The ICE dollar index ....More>>>
The management of regulatory affairs essentially contributes to the overall success of new drug development – both at early pre-marketing stages and at all times post-marketing. This means that a biotech or pharma company’s regulatory affairs personnel will be heavily involved in all stages of new drug development both prior to and after an FDA approval.